Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 5,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Completed Not applicable Interventional Results available

An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma

NCT02591472
View directory record Official record
Conditions
Musculoskeletal Injury Trauma
Interventions
Integrated care (ICare), Usual Care (UsCare), Patient-Reported Outcomes Measurement Information System, Lower Extremity Gain Scale (LEGS), Dynamometer, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11)
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activity, Gait, and Efficacy (AGE II): Functional Limitations and Quality of Life

NCT01030419
View directory record Official record
Conditions
Aging
Interventions
Home-based, DVD-delivered physical activity, Usual care/Wait list
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
65 Years to 85 Years
Enrollment
410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 23, 2026, 12:13 AM EDT
Terminated Phase 1 Interventional

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

NCT02991651
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
IRX4204, erlotinib
Drug
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 1 Interventional

CCI-779 in Treating Patients With Advanced Solid Tumors

NCT00003712
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temsirolimus
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
2
States / cities
Rochester, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

NCT02958865
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
60
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 12:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 12:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PET and MRI Brain Imaging of Bipolar Disorder

NCT01880957
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Unipolar Depression
Interventions
Lithium, Lamotrigine
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 1 Interventional

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

NCT00003765
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
51
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 23, 2026, 12:13 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban

NCT02213029
View directory record Official record
Conditions
Embryo Transfer
Interventions
Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional

Brain Machine Interface (BMI) in Subjects Living With Quadriplegia

NCT02564419
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Medtronic Activa PC+S
Device
Lead sponsor
Jonathan Jagid
Other
Eligibility
22 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study Investigating The Effects Of An Ankle Rehabilitation Program On High School Athletes With Ankle Instability

NCT03447652
View directory record Official record
Conditions
Chronic Ankle Instability, Ankle Sprains, Ankle Rehabilitation
Interventions
Resistance Band Ankle Rehabilitation, Biomechanical Ankle Platform System Rehabilitation, Combination Rehabilitation
Other
Lead sponsor
Georgia State University
Other
Eligibility
15 Years to 18 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • College Park, Georgia • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 23, 2026, 12:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

NCT03100149
View directory record Official record
Conditions
Parkinson's Disease
Interventions
RO7046015, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity Incentives

NCT03037658
View directory record Official record
Conditions
Physical Activity
Interventions
Offering a financial incentive to increase walking
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional

Clinical Evaluation of the V5-LU01 AI Software in Thoracic CT for V5med Inc.

NCT06514248
View directory record Official record
Conditions
Lung Cancer
Interventions
V5med Lung AI
Device
Lead sponsor
V5med Inc.
Industry
Eligibility
55 Years to 77 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 23, 2026, 12:13 AM EDT
Recruiting Phase 1 Interventional

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

NCT06613217
View directory record Official record
Conditions
Relapsed Adult AML
Interventions
zelenirstat
Drug
Lead sponsor
Pacylex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

NCT02374047
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
CAT-2054, Placebo, CAT-2054-C, Atorvastatin
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 23, 2026, 12:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

NCT01035658
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
Pazopanib, Doxil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Fort Myers, Florida • Orlando, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer

NCT00278148
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, Erlotinib, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Nathan Pennell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 1 Interventional

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT05006885
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Tucson, Arizona • Montclair, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Not applicable Interventional Results available

Study of Low Level Laser Therapy to Treat Chronic Heel Pain Arising From Plantar Fasciitis

NCT01835743
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Erchonia HPS Laser, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Mesa, Arizona • Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 23, 2026, 12:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

NCT01251315
View directory record Official record
Conditions
Oxidative Stress
Interventions
Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 23, 2026, 12:13 AM EDT